Midterm performance of a novel restorative pulmonary valved conduit: preclinical results

Aims:The Xeltis bioabsorbable pulmonary valved conduit (XPV), designed to guide functional restoration of patients' own tissue, is potentially more durable than current pulmonary bioprosthetic valves/valved conduits.The aim of this study was to assess the haemodynamic performance of the novel XPV implanted in an ovine model. Methods and results:The XPV was surgically implanted in adult sheep under general anaesthesia and cardiopulmonary bypass (XPV group, n=20).Sheep that received a Hancock bioprosthetic pulmonary valved conduit served as a control group (HPV group, n=3).Transthoracic echocardiograms from VARC-2 recommended time points at 3, 6, 9, 12, 18 and 24 months (XPV group) and at 3 and 6 months (HPV group) after the procedure were analysed in an independent core laboratory.The primary endpoint was favourable valved conduit performance, defined as peak systolic pressure gradient <40 mmHg, no severe pulmonary regurgitation (PR), and a maximum conduit patency index of -20%.In the latter, negative values denote luminal narrowing and vice versa.The valvular peak systolic pressure gradient (mmHg) was 25.6±9.7 (3 months), 19.6±7.1 (6 months), 10.0±9.2 (24 months) in the XPV group and 18.4±6.6(3 months), 17.7±4.6(6 months) in the HPV group.The patency index (%) of the conduit at the valvular level was +30.3±13.6 (6 months) and +64.1±1.4 (24 months) in the XPV group and +2.0±15.9(6 months) in the HPV group.PR was trace or mild at all visits, except in one animal with persistent moderate PR in the XPV group, up to 24 months. Conclusions:The XPV showed a favourable and durable haemodynamic performance (up to two years after implantation), without conduit narrowing/obstruction or severe regurgitation.